Protamine inhibits tissue factor-initiated extrinsic coagulation

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Inflammation can enhance extrinsic coagulation, potentially leading to disseminated intravascular coagulation and cardiovascular issues.
• The mechanisms and management of this hypercoagulation remain incompletely understood.
• Bacterial endotoxins, such as lipopolysaccharide (LPS), are known triggers of coagulation cascades.

Purpose of the Study:

• To investigate the capacity of protamine to counteract LPS-induced extrinsic coagulation.
• To elucidate the specific molecular targets and mechanisms of protamine's anticoagulant activity within the extrinsic pathway.

Main Methods:

• In vitro studies using human monocytes and THP-1 leukaemia cells exposed to LPS.
• Cell-free assays with rabbit brain thromboplastin (rbTF).
• Prothrombin time and thrombin time assays, chromogenic substrate assays, and Western blot analysis to assess coagulation factor activation and activity.

Main Results:

• Protamine significantly inhibited LPS-induced extrinsic coagulation in cellular and cell-free models.
• Protamine prolonged prothrombin time but did not alter thrombin time, indicating specific downregulation of the extrinsic pathway.
• Protamine specifically inhibited the activation of factor VII (FVII) to FVIIa, particularly in tissue factor (TF)-catalysed reactions, without affecting FX activation or FVIIa/FXa amidolytic activity.

Conclusions:

• Protamine effectively downregulates the TF-initiated extrinsic coagulation cascade by inhibiting FVII activation.
• Protamine demonstrates significant anticoagulant potential in managing inflammation-associated hypercoagulation.
• These findings highlight protamine as a potential therapeutic agent for conditions involving extrinsic pathway overactivation.